Ampa Study (a Mirroring Clinical Practice Study of Perampanel in Adults and Adolescents) Design: Real-world Prospective Study of Perampanel As Add-on Therapy for Focal-Onset Seizures

Perampanel is a once-daily oral anti-seizure medication (ASM) for focal-onset seizures (FOS) and generalized tonic-clonic seizures. The AMPA Study (501; NCT04257604) was a multicenter, prospective, observational study conducted in Italy to assess the effectiveness and safety of perampanel received as add-on therapy in patients aged ≥12 years with FOS in a real-world setting. We present the design of the AMPA Study.